AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25420534 — intervention group
Group type: EXPERIMENTAL
Intervention: Armillarisin A 10 mg enema in 100 ml saline
Number of subjects: 60
Study 25420534 — intervention group
Group type: EXPERIMENTAL
Intervention: Armillarisin A 10 mg and dexamethasone 5 mg enema in 100 ml saline
Number of subjects: 60
Study 25420534 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone 5 mg enema in 100 ml saline
Number of subjects: 60
Study 23897585 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro-surfactant protein B (pro-SFTPB) nondetectable status
Number of subjects: 525
Study 23897585 — intervention group
Group type: EXPERIMENTAL
Intervention: Detectable levels of pro-SFTPB
Number of subjects: 525
Study 21936902 — intervention group
Group type: EXPERIMENTAL
Intervention: Red blood cell (RBC) transfusion within 24 hours of randomization
Number of subjects: 285
Study 21936902 — intervention group
Group type: EXPERIMENTAL
Intervention: Red blood cell (RBC) transfusion within 24 hours of randomization among subset meeting transfusion criteria
Number of subjects: 285
Study 19769912 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal program (MP) consisting of 17 group sessions of 1.75 hours and one individual session of 45 minutes, including psychological units, stabilization exercises, and ergonomic training
Number of subjects: 169
Study 19769912 — intervention group
Group type: COMPARATOR
Intervention: General exercise program (EP) consisting of 11 group sessions of 1 hour focusing on physical strengthening and stretching exercises
Number of subjects: 169
Study 17012628 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan plus inhaled iloprost (combination group)
Number of subjects: 40
Study 17012628 — intervention group
Group type: COMPARATOR
Intervention: Bosentan alone (control group)
Number of subjects: 40
Study 15315111 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal replacement (200-calorie meal)
Number of subjects: 47
Study 15315111 — intervention group
Group type: COMPARATOR
Intervention: Low-calorie diet (control group)
Number of subjects: 47
Study 15315111 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal replacement
Number of subjects: 47
Study 15315111 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal replacement with balanced low-calorie diet
Number of subjects: 47
Study 11692092 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal heparin
Number of subjects: 10
Study 9113630 — intervention group
Group type: EXPERIMENTAL
Intervention: High-AA diet (1.5 g/d of AA in the form of a triglyceride containing 50% AA)
Number of subjects: 0
Study 9113630 — intervention group
Group type: COMPARATOR
Intervention: Low-AA diet (210 mg/d of AA)
Number of subjects: 0
Study 8190677 — intervention group
Group type: EXPERIMENTAL
Intervention: Solcotrans Orthopaedic Drainage Reinfusion System
Number of subjects: 24
Study 8190677 — intervention group
Group type: COMPARATOR
Intervention: Control group (no drainage reinfusion)
Number of subjects: 24
Study 3401273 — intervention group
Group type: EXPERIMENTAL
Intervention: Berniter
Number of subjects: 23
Study 3401273 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone-17-valerate (Bet-17-v)
Number of subjects: 23
Study 31169912 — intervention group
Group type: EXPERIMENTAL
Intervention: MI plus omega-3
Number of subjects: 1588
Study 31169912 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 alone
Number of subjects: 1588
Study 31169912 — intervention group
Group type: EXPERIMENTAL
Intervention: MI plus placebo
Number of subjects: 1588
Study 31169912 — intervention group
Group type: COMPARATOR
Intervention: Placebo alone
Number of subjects: 1588
Study 31169912 — intervention group
Group type: EXPERIMENTAL
Intervention: MI plus omega-3 (sensitivity analysis)
Number of subjects: 1588
Study 28482877 — intervention group
Group type: EXPERIMENTAL
Intervention: eRAPID intervention (internet-based system for self-reporting adverse events)
Number of subjects: 504
Study 28482877 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 504
Study 24803170 — intervention group
Group type: EXPERIMENTAL
Intervention: Drivers who made ratings of their sleepiness, likelihood of falling asleep, and likelihood of crashing at prompts occurring at 200s intervals throughout the drive.
Number of subjects: 90
Study 24803170 — intervention group
Group type: EXPERIMENTAL
Intervention: Drivers who rated sleepiness and likelihood of falling asleep at prompts but pressed a button on the steering wheel if they felt they were near to crashing.
Number of subjects: 90
Study 24803170 — intervention group
Group type: COMPARATOR
Intervention: Drivers who made no ratings and only used a button-press if they felt a crash was likely.
Number of subjects: 90
Study 22923669 — intervention group
Group type: EXPERIMENTAL
Intervention: Six-step CVD risk communication
Number of subjects: 261
Study 22923669 — intervention group
Group type: COMPARATOR
Intervention: Standard managed care (Control)
Number of subjects: 261
Study 18982335 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg tramadol (Group T)
Number of subjects: 80
Study 18982335 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg tramadol with 0.5 mg kg(‐1) ketamine (Group TK)
Number of subjects: 80
Study 18982335 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg ropivacaine (Group R)
Number of subjects: 80
Study 18982335 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg ropivacaine with 0.5 mg kg(‐1) ketamine (Group RK)
Number of subjects: 80
Study 17907228 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganoderma lucidum (4 gm) and San Miao San (2.4 gm) daily
Number of subjects: 32
Study 17907228 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 17907228 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganoderma lucidum and San Miao San
Number of subjects: 32
Study 16238906 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 10 mg/day
Number of subjects: 357
Study 16238906 — intervention group
Group type: COMPARATOR
Intervention: Citalopram 20 mg/day
Number of subjects: 357
Study 11907486 — intervention group
Group type: EXPERIMENTAL
Intervention: Saquinavir 50 mg/kg tid alone
Number of subjects: 0
Study 11907486 — intervention group
Group type: EXPERIMENTAL
Intervention: Saquinavir 50 mg/kg tid plus nelfinavir 30 mg/kg tid
Number of subjects: 0
Study 11907486 — intervention group
Group type: EXPERIMENTAL
Intervention: Saquinavir (any dosage)
Number of subjects: 0
Study 10096977 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated cardiopulmonary bypass equipment
Number of subjects: 29
Study 10096977 — intervention group
Group type: COMPARATOR
Intervention: Uncoated cardiopulmonary bypass equipment
Number of subjects: 29
Study 7809840 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacron grafts
Number of subjects: 60
Study 7809840 — intervention group
Group type: COMPARATOR
Intervention: PTFE grafts
Number of subjects: 60
Study 2082316 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac active/heparin dummy
Number of subjects: 12
Study 2082316 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac active/heparin active
Number of subjects: 12
Study 2082316 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin active
Number of subjects: 12
Study 2082316 — intervention group
Group type: COMPARATOR
Intervention: Ketorolac dummy/heparin active
Number of subjects: 12
Study 2082316 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac
Number of subjects: 12
Study 6995513 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextroamphetamine (0.5 mg/kg)
Number of subjects: 29
Study 6995513 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 31952553 — intervention group
Group type: EXPERIMENTAL
Intervention: CKDu patients
Number of subjects: 180
Study 31952553 — intervention group
Group type: COMPARATOR
Intervention: Control groups
Number of subjects: 180
Study 29374963 — intervention group
Group type: EXPERIMENTAL
Intervention: Unified Protocol for Transdiagnostic Treatment of Emotional Disorders in Children (UP‐C)
Number of subjects: 47
Study 29374963 — intervention group
Group type: COMPARATOR
Intervention: Active, anxiety‐focused intervention (Control)
Number of subjects: 47
Study 26987102 — intervention group
Group type: EXPERIMENTAL
Intervention: Moldable skin barrier
Number of subjects: 104
Study 26987102 — intervention group
Group type: COMPARATOR
Intervention: Conventional skin barrier
Number of subjects: 104
Study 25833066 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial lysate (OM‐85 Broncho‐Vaxom)
Number of subjects: 60
Study 25833066 — intervention group
Group type: COMPARATOR
Intervention: Conventional inhaled corticosteroid (ICS)
Number of subjects: 60
Study 26060627 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional intelligence training (12 sessions, 50 minutes each, twice a week)
Number of subjects: 40
Study 26060627 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 40
Study 21372765 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice daily 1 sachet of probiotic + high-fibre diet (Group B)
Number of subjects: 50
Study 21372765 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice daily 2 sachets of probiotic + high-fibre diet (Group C)
Number of subjects: 50
Study 21372765 — intervention group
Group type: COMPARATOR
Intervention: High-fibre diet alone (Group A)
Number of subjects: 50
Study 19726394 — intervention group
Group type: EXPERIMENTAL
Intervention: Mastery intervention
Number of subjects: 330
Study 17348994 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple combination (TC) cream applied once daily for 8 weeks
Number of subjects: 120
Study 17348994 — intervention group
Group type: COMPARATOR
Intervention: Hydroquinone (HQ) cream applied twice daily for 8 weeks
Number of subjects: 120
Study 17348994 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple combination (TC) cream and Hydroquinone (HQ) cream
Number of subjects: 120
Study 17190958 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine (600 mg BID)
Number of subjects: 32
Study 17190958 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy without oxcarbazepine
Number of subjects: 32
Study 14567803 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125% bupivacaine 30 ml instilled into the pelvic cavity and over the diaphragmatic vault (Group A)
Number of subjects: 134
Study 14567803 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% lidocaine 30 ml instilled (Group B)
Number of subjects: 134
Study 14567803 — intervention group
Group type: COMPARATOR
Intervention: Normal saline 30 ml instilled (Group C)
Number of subjects: 134
Study 14567803 — intervention group
Group type: COMPARATOR
Intervention: No intraperitoneal agent (Group D)
Number of subjects: 134
Study 10469856 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine hemodialysis (135-140 mEq/L sodium bath)
Number of subjects: 12
Study 10469856 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated ultrafiltration
Number of subjects: 12
Study 10469856 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated diffusion
Number of subjects: 12
Study 10469856 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypernatric hemodialysis (150-155 mEq/L sodium bath)
Number of subjects: 12
Study 10469856 — intervention group
Group type: COMPARATOR
Intervention: Isolated membrane (sham procedure)
Number of subjects: 12
Study 10469856 — intervention group
Group type: COMPARATOR
Intervention: Recirculation (sham procedure)
Number of subjects: 12
Study 8740048 — intervention group
Group type: EXPERIMENTAL
Intervention: SDZ EAA 494 single dose (1-50 mg)
Number of subjects: 0
Study 8740048 — intervention group
Group type: EXPERIMENTAL
Intervention: SDZ EAA 494 multiple doses (25 mg once or twice daily for 1 week)
Number of subjects: 0
Study 8740048 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 1874211 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapleural bupivacaine (10 ml of 0.25% bupivacaine with 1:200,000 adrenaline every 8 h for 4 days)
Number of subjects: 20
Study 1874211 — intervention group
Group type: COMPARATOR
Intervention: Intrapleural saline (10 ml normal saline every 8 h for 4 days)
Number of subjects: 20
Study 1874211 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapleural bupivacaine
Number of subjects: 20
Study 1874211 — intervention group
Group type: COMPARATOR
Intervention: Intrapleural saline
Number of subjects: 20
Study 6577782 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil, 1,200 mg/day
Number of subjects: 0
Study 6577782 — intervention group
Group type: COMPARATOR
Intervention: Gemfibrozil therapy
Number of subjects: 0
Study 30520691 — intervention group
Group type: EXPERIMENTAL
Intervention: Oleic acid (long-chain fatty acid)
Number of subjects: 20
Study 30520691 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (triglyceride)
Number of subjects: 20
Study 30520691 — intervention group
Group type: COMPARATOR
Intervention: Independent of lipid loads
Number of subjects: 20
Study 27256488 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity (MVPA)
Number of subjects: 386
Study 27256488 — intervention group
Group type: EXPERIMENTAL
Intervention: Light physical activity
Number of subjects: 386
Study 26255021 — intervention group
Group type: COMPARATOR
Intervention: Control group (0 T-junctions)
Number of subjects: 20
Study 26255021 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 T-junction
Number of subjects: 20
Study 26255021 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 T-junctions
Number of subjects: 20
Study 26255021 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 T-junctions
Number of subjects: 20
Study 23386757 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BTX‐A)
Number of subjects: 36
Study 23386757 — intervention group
Group type: COMPARATOR
Intervention: Intralesional steroids
Number of subjects: 36
Study 21574800 — intervention group
Group type: EXPERIMENTAL
Intervention: Medpor® wedge implant
Number of subjects: 25
Study 19687575 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual physical therapy and exercise (MTEX)
Number of subjects: 60
Study 19687575 — intervention group
Group type: COMPARATOR
Intervention: Electrophysical agents and exercise (EPAX)
Number of subjects: 60
Study 16488299 — intervention group
Group type: EXPERIMENTAL
Intervention: ISA247 0.5 mg/kg/d
Number of subjects: 201
Study 16488299 — intervention group
Group type: EXPERIMENTAL
Intervention: ISA247 1.5 mg/kg/d
Number of subjects: 201
Study 16488299 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study 15253966 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue Doppler (TD) velocities in children with DCM
Number of subjects: 54
Study 15253966 — intervention group
Group type: EXPERIMENTAL
Intervention: Tricuspid Ea velocity < 8.5 cm/s
Number of subjects: 54
Study 15253966 — intervention group
Group type: EXPERIMENTAL
Intervention: LVEF < 30%
Number of subjects: 54
Study 15253966 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined LVEF < 30% and tricuspid Ea < 11.5 cm/s
Number of subjects: 54
Study 15253966 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 54
Study 11079844 — intervention group
Group type: EXPERIMENTAL
Intervention: SAGE (Self‐study Acceleration with Graphic Evidence) tutorial system
Number of subjects: 79
Study 9142924 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan
Number of subjects: 8
Study 9142924 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 8409070 — intervention group
Group type: EXPERIMENTAL
Intervention: Flosequinan 50, 100 or 150 mg daily (short-term administration)
Number of subjects: 47
Study 8409070 — intervention group
Group type: EXPERIMENTAL
Intervention: Flosequinan 50, 100 or 150 mg daily (long-term administration after 8 weeks)
Number of subjects: 47
Study 3898833 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate (1 g in the morning and 2 g at night)
Number of subjects: 61
Study 3898833 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 3898833 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 61
Study 29391385 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nitazoxanide
Number of subjects: 100
Study 29391385 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 26966107 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (PROP group, n = 27)
Number of subjects: 56
Study 26966107 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (MID group, n = 29)
Number of subjects: 56
Study 26966107 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (PROP group)
Number of subjects: 56
Study 26966107 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (MID group)
Number of subjects: 56
Study 25612907 — intervention group
Group type: EXPERIMENTAL
Intervention: Oatmeal
Number of subjects: 36
Study 25612907 — intervention group
Group type: EXPERIMENTAL
Intervention: Corn flakes
Number of subjects: 36
Study 25612907 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 36
Study 23447916 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E 400 IU/day for 5 days, starting 2 days before menstruation for 2 cycles
Number of subjects: 120
Study 23447916 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 21903895 — intervention group
Group type: EXPERIMENTAL
Intervention: Total and free E(2)
Number of subjects: 3120
Study 21903895 — intervention group
Group type: EXPERIMENTAL
Intervention: SHBG, IGF1, and PTH
Number of subjects: 3120
Study 21903895 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of bone markers (β‐cTX and P1NP)
Number of subjects: 3120
Study 21903895 — intervention group
Group type: EXPERIMENTAL
Intervention: Total or free testosterone
Number of subjects: 3120
Study 19041044 — intervention group
Group type: EXPERIMENTAL
Intervention: IHM-guided care
Number of subjects: 70
Study 19041044 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 70
Study 16324850 — intervention group
Group type: COMPARATOR
Intervention: Shoulder muscle activation patterns measured by surface electromyography (sEMG) during four functional tasks
Number of subjects: 25
Study 16324850 — intervention group
Group type: COMPARATOR
Intervention: Voluntary response index (VRI) calculated for EMG magnitude and similarity index (SI)
Number of subjects: 25
Study 12711404 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval medication
Number of subjects: 286
Study 12711404 — intervention group
Group type: COMPARATOR
Intervention: Continuous medication
Number of subjects: 286
Study 12742493 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (2 mg/d) in one-haplotype living-related kidney allografts
Number of subjects: 193
Study 12742493 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus (2 mg/kg per day) in one-haplotype living-related kidney allografts
Number of subjects: 193
Study 12742493 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (2 mg/day) in fully mismatched living kidney allografts
Number of subjects: 193
Study 12742493 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (target trough concentrations 8-12 ng/mL) in high-risk black ethnicity recipients
Number of subjects: 193
Study 12742493 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (target trough concentrations 15-20 ng/mL) in high-risk black ethnicity recipients
Number of subjects: 193
Study 12742493 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (28 days after angioplasty) in high-risk patients
Number of subjects: 193
Study 10321420 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral moxifloxacin (100 mg)
Number of subjects: 10
Study 10321420 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous moxifloxacin (100 mg, 60-minute infusion)
Number of subjects: 10
Study 10321420 — intervention group
Group type: EXPERIMENTAL
Intervention: Both oral and IV formulations
Number of subjects: 10
Study 8726604 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 47
Study 8726604 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 47
Study 1827086 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg fosinopril
Number of subjects: 220
Study 1827086 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg fosinopril
Number of subjects: 220
Study 1827086 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg fosinopril
Number of subjects: 220
Study 1827086 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study 1827086 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril (10-80 mg) with or without chlorthalidone
Number of subjects: 220
Study 1827086 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril
Number of subjects: 220
Study 6887757 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of cotrimoxazole, polymyxin B and nystatin (group A)
Number of subjects: 78
Study 6887757 — intervention group
Group type: COMPARATOR
Intervention: Combination of nalidixic acid, polymyxin B, neomycin and nystatin (group B)
Number of subjects: 78
Study 31974022 — intervention group
Group type: EXPERIMENTAL
Intervention: Prompt describing MDMA's effects
Number of subjects: 278
Study 31974022 — intervention group
Group type: EXPERIMENTAL
Intervention: Prompt describing adulterants as inert 'filler'
Number of subjects: 278
Study 31974022 — intervention group
Group type: EXPERIMENTAL
Intervention: Prompt describing adulterants as pharmacologically-active, potentially-harmful compounds
Number of subjects: 278
Study 31974022 — intervention group
Group type: COMPARATOR
Intervention: No prompt
Number of subjects: 278
Study 31974022 — intervention group
Group type: EXPERIMENTAL
Intervention: All prompts
Number of subjects: 278
Study 31974022 — intervention group
Group type: EXPERIMENTAL
Intervention: Inelastic purchasing
Number of subjects: 278
Study 30964598 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Nordic diet
Number of subjects: 68
Study 30964598 — intervention group
Group type: COMPARATOR
Intervention: Average habitual Nordic diet
Number of subjects: 68
Study 28121188 — intervention group
Group type: EXPERIMENTAL
Intervention: sRPE assessed immediately at the end of training sessions
Number of subjects: 51
Study 28121188 — intervention group
Group type: EXPERIMENTAL
Intervention: sRPE assessed 30 min after training sessions
Number of subjects: 51
Study 28121188 — intervention group
Group type: EXPERIMENTAL
Intervention: sRPE assessed 7 h after training sessions
Number of subjects: 51
Study 28121188 — intervention group
Group type: EXPERIMENTAL
Intervention: sRPE assessed the next morning (20 h after) for confirmation
Number of subjects: 51
Study 26600270 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 infusion
Number of subjects: 35